NASDAQ:AGIO
Agios Pharmaceuticals Stock News
$36.34
-1.20 (-3.20%)
At Close: May 31, 2024
Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
07:00am, Tuesday, 05'th Jan 2021
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today anno
Agios Pharmaceuticals: A Pivot From Cancer Metabolism To Rare Diseases
08:54am, Thursday, 31'st Dec 2020
Agios recently sold off its oncology business to Servier for $2B ($1.8B in cash) creating a unique situation to buy a company with a strong drug development track record. With 2 drug approvals under i
Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?
09:02am, Wednesday, 23'rd Dec 2020
Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.
Agios (AGIO) to Sell Oncology Drugs to Servier for $2B, Stock Up
11:17am, Tuesday, 22'nd Dec 2020
Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely focus on developing treatments for genetically defined diseases.
4 Reasons Agios' Oncology Deal Should Please Investors
07:39am, Tuesday, 22'nd Dec 2020
Agios' newly revamped business strategy is an extreme departure from the company's original mission, but it's a great deal for shareholders.
Why Agios Pharmaceuticals Stock Is Soaring Today
11:44am, Monday, 21'st Dec 2020
Investors applauded the company's planned sale of its oncology portfolio.
Agios Pharma's Big Bet on Anemia
09:54am, Monday, 21'st Dec 2020
The announcement that Agios Pharmaceuticals Inc. (NASDAQ: AGIO) will be streamlining its portfolio sent shares sharply higher early Monday.
Agio's shares jump 20% after announcing plans to sell cancer portfolio
07:39am, Monday, 21'st Dec 2020
Shares of Agios Pharmaceuticals Inc. soared 20.6% in premarket trading on Monday after the company said it is selling its oncology portfolio to Servier, a privately held French pharmaceutical company.
– Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building on its Scientific Expertise in Cellular Metabolism and PK Activatio
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
04:30pm, Monday, 07'th Dec 2020
– Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Patients , Decreased Markers of Hemolysis, Reduced 2,3-DPG and Increased ATP –
Agios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias
07:00am, Monday, 30'th Nov 2020
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced t
Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020
07:00am, Wednesday, 25'th Nov 2020
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced t
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease
04:30pm, Thursday, 12'th Nov 2020
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced
Agios Pharmaceuticals' (AGIO) CEO Jackie Fouse on Q3 2020 Results - Earnings Call Transcript
11:54pm, Thursday, 05'th Nov 2020
Agios Pharmaceuticals' (AGIO) CEO Jackie Fouse on Q3 2020 Results - Earnings Call Transcript
Agios Pharmaceuticals: Q3 Earnings Insights
08:23am, Thursday, 05'th Nov 2020
Shares of Agios Pharmaceuticals (NASDAQ:AGIO) were unchanged after the company reported Q3 results.
